Russell Frank Company’s Aratana Therapeutics, Inc. PETX Stock Holding History

Russell Frank Company’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-56,948	Closed	-$912K	–	3123
2015 Q1	$912K	Buy	56,948 +5,661	+11%	+$101K	﹤0.01%	2185
2014 Q4	$908K	Buy	+51,287	New	+$639K	﹤0.01%	2187

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Russell Frank Company's PETX Position: Q2 2015 in Review

Russell Frank Company sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2015, closing a stake of 56,948 shares — an estimated $912K sold.

Russell Frank Company first reported a position in PETX in Q4 2014 and held it in 2 quarters. The position peaked at $912K in Q1 2015. 92 funds tracked by Wall St. Rank hold PETX as of Q2 2015.

Russell Frank Company reported no remaining Aratana Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
Russell Frank Company sold 56,948 Aratana Therapeutics, Inc. shares in Q2 2015, an estimated $912K.
Russell Frank Company first reported a position in Aratana Therapeutics, Inc. in Q4 2014 and held it in 2 quarters.
Russell Frank Company's Aratana Therapeutics, Inc. position peaked at $912K in Q1 2015.
92 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2015.

Based on Russell Frank Company's 13F filing for Q2 2015, filed 13 Aug 2015.